Pipeline Database

UB656

LIV-1

Submit a Project Finished Dosage Form DB

UB656

TargetsLIV-1

IndicationsBreast cancer; Prostate cancer; Ovarian cancer; Endometrial cancer

ClinicalCN - II

TherapeuticsOncology

ModalitiesADC

Exclusive Summary

Antibodies targeting LIV-1 are conjugated to small molecule toxins. UB656 recognizes and binds to LIV-1 on the surface of tumor cells, and the ADC-target complex enters the lysosomes of tumor cells through endocytosis, releasing small molecule toxins to kill tumor cells.

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here